ID
25747
Beskrivning
Study ID: 101468/169 Clinical Study ID: 101468/169 Study Title:A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment with Ropinirole CR as Adjunctive Therapy in Patients with Parkinson's Disease who are not Optimally Controlled on L-dopa Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00381472 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Parkinson Disease This is the L-Dopa Medication form.
Nyckelord
Versioner (2)
- 9/17/17 9/17/17 -
- 9/28/17 9/28/17 -
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
September 17, 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
GSK Ropinirole in Patients Suffering from Parkinsons Disease L-Dopa Medication 101468/169 NCT00381472
GSK Ropinirole in Patients Suffering from Parkinsons Disease L-Dopa Medication 101468/169 NCT00381472
Similar models
GSK Ropinirole in Patients Suffering from Parkinsons Disease L-Dopa Medication 101468/169 NCT00381472
C0013227 (UMLS CUI [1,2])
C0023570 (UMLS CUI [1,3])
C0023570 (UMLS CUI [1,2])
C0023570 (UMLS CUI [1,3])
C0869039 (UMLS CUI [1,4])
C0013227 (UMLS CUI [1,2])
C0023570 (UMLS CUI [1,3])
C0013227 (UMLS CUI [1,2])
C0023570 (UMLS CUI [1,3])
C0808070 (UMLS CUI [1,2])
C0023570 (UMLS CUI [1,3])
C0023570 (UMLS CUI [1,2])
C0023570 (UMLS CUI [1,2])